Ipca Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ipca Laboratories Limited, the promoter of Krebs Biochemicals and Industries, has filed an annual declaration with the stock exchanges under SEBI Takeover Regulations. The declaration confirms that Ipca has not created any encumbrance — meaning no pledge, lien, or similar charge — on the equity shares it holds in Krebs Biochemicals during the financial year ended March 31, 2026. This is a routine annual compliance filing required from promoters under Regulation 31(4). No change in the nature of shareholding or any encumbrance activity is being reported. The filing was signed by Ipca's Corporate Counsel and Company Secretary, Harish Kamath.
This is a routine regulatory disclosure with no material impact on the stock. It simply reassures investors that the promoter's stake in Krebs Biochemicals remains free of any pledges or encumbrances, which is a neutral-to-slightly-positive signal for shareholding stability.